Please join Carrie Buchanan, MD, Fragile X Program Director at Greenwood Genetic Center, for a webinar on World Fragile X Day, July 22, 2024, at 11 AM ET. She will discuss how individuals with Fragile X experience high levels of anxiety, which can manifest in many different ways.
Read moreautism
Fragile X Treatment Target Emerges from Neurolixis & FRAXA Collaboration
![Fragile X Treatment Target Emerges from Neurolixis & FRAXA Collaboration](https://www.fraxa.org/wp-content/uploads/2024/06/serotonin-and-silhouette-of-a-man-head-720x300.jpg)
A new treatment target for Fragile X syndrome has emerged from multiple research labs and a pharmaceutical startup. Neurolixis, a FRAXA pharma partner, has announced a new Fragile X development program.
Read moreBK Channel Openers: A New Drug for Fragile X Is Ready for Clinical Trials
![BK Channel Openers: A New Drug for Fragile X Is Ready for Clinical Trials](https://www.fraxa.org/wp-content/uploads/2024/05/Restoring-Synapses-BK-Channel-Opener-720x300.png)
Discover the promising new BK channel opener, SPG601, now entering clinical trials for Fragile X syndrome. Learn about its potential to restore synaptic function and address core symptoms.
Read moreRecruiting: Tetra Therapeutics Phase 3 Clinical Trial of Zatolmilast in Fragile X Syndrome
![Recruiting: Tetra Therapeutics Phase 3 Clinical Trial of Zatolmilast in Fragile X Syndrome Tetra Therapeutics Phase 3 Clinical Trial of Zatolmilast in Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2024/02/Tetra-Therapeutics-Phase-3-Clinical-Trial-of-Zatolmilast-in-Fragile-X-Syndrome-720x300.png)
Tetra Therapeutics has launched large scale clinical trials of their phosphodiesterase (PDE) inhibitor for males ages 9-45 with Fragile X syndrome. FRAXA Research Foundation’s basic and translational research pointed the way to phosphodiesterase inhibitors to treat Fragile X.
Read moreRenewed Hope: Navigating Towards a Cure for Fragile X Syndrome
![Renewed Hope: Navigating Towards a Cure for Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2024/04/Sutton_Todd_Mills_Rodriguez_015-e1712066000308-720x300.jpg)
Discover how Dr. Peter Todd’s latest Fragile X Syndrome research offers hope for advanced treatments and a possible cure, marking a new era in FXS therapy.
Read morePharmacologically Activating mGluR7 as a Novel Therapy for Fragile X Syndrome
![Pharmacologically Activating mGluR7 as a Novel Therapy for Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2023/04/Tsai-Kumar-720x300.jpg)
Join Dr. Tsai and Dr. Kumar on a journey into novel treatment avenues for Fragile X syndrome. Learn how activating mGluR7 could be a game-changer, opening up uncharted therapeutic territory.
Read moreCallum Cup’s Big Win: Millburn Charity Soccer Raises $26K for Fragile X Research
![Callum Cup’s Big Win: Millburn Charity Soccer Raises $26K for Fragile X Research Callum Cup 2023 Group](https://www.fraxa.org/wp-content/uploads/2023/12/Group-720x300.png)
Discover the inspiring story of the Callum Cup in Millburn, NJ – a charity soccer match that raised over $26,000 for Fragile X research. Join us in celebrating community spirit and a commitment to a vital cause.
Read more$100,000 Matching Challenge From The Robert & Ardis James Foundation
![$100,000 Matching Challenge From The Robert & Ardis James Foundation](https://www.fraxa.org/wp-content/uploads/2022/12/Ralph-James-quote-2022b-720x300.png)
We are thrilled to announce FRAXA Research Foundation’s most significant and unique matching challenge of the year, thanks to the Robert & Ardis James Foundation. This challenge will help us bring top new talent to Fragile X research.
Read moreSupport the Stevenson Family Campaign
![Support the Stevenson Family Campaign](https://www.fraxa.org/wp-content/uploads/2022/11/Stevenson-2023-02-720x300.jpg)
The march of time renews the commitment we made to a special needs community 25 years ago. We vowed to dream big and never give up until there were effective treatments available and eventually a cure for Fragile X syndrome, the most commonly inherited cause of intellectual disabilities and autism.
Read moreSomatosensory Processing as a Therapeutic Target for Fragile X Syndrome
![Somatosensory Processing as a Therapeutic Target for Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2023/04/Leena-E.-Williams-Andrew-Stanfield-Damien-Wright--720x300.jpg)
Awarded a FRAXA Research grant, Dr. Andrew Stanfield, Dr. Leena E. Williams, and Dr. Damien Wright are set to explore somatosensory processing (sense of touch) in Fragile X syndrome at the University of Edinburgh. Their aim? A noninvasive touch test that could set the stage for future clinical trials in FXS.
Read moreAntisense Oligonucleotides (ASOs) to restore FMRP in Human Fragile X Cerebral Organoids
![Antisense Oligonucleotides (ASOs) to restore FMRP in Human Fragile X Cerebral Organoids](https://www.fraxa.org/wp-content/uploads/2023/06/Richter-Shah-Berry-Kravis-Watts-Banbury-Meeting-720x300.jpg)
Explore Dr. Richter’s encouraging results with ASOs for Fragile X syndrome. A $100,000 grant now fuels pivotal studies needed to advance toward ASO therapy.
Read moreFRAXA Research Foundation Partners with Autism BrainNet
![FRAXA Research Foundation Partners with Autism BrainNet](https://www.fraxa.org/wp-content/uploads/2023/08/FRAXA-Autism-BrainNet-720x300.png)
Discover how FRAXA Research Foundation’s collaboration with Autism BrainNet accelerates Fragile X syndrome research by collecting vital postmortem brain tissue. Dive into the significance of brain studies for deeper insights and potential therapeutic interventions.
Read moreASOs and Fragile X: Addressing the Most Asked Questions
![ASOs and Fragile X: Addressing the Most Asked Questions](https://www.fraxa.org/wp-content/uploads/2023/08/Fragile-X-Antisense-Oligonucleotide-therapy-720x300.jpg)
Explore the potential of ASOs in treating Fragile X syndrome & FXTAS. Dive into a comprehensive Q&A addressing key questions and breakthrough findings.
Read moreIn Memory of Garret
![In Memory of Garret](https://www.fraxa.org/wp-content/uploads/2023/08/Garret-Peacock-Volker--e1691776959377-720x300.jpg)
Honor Garret Peacock Volker’s extraordinary life by supporting FRAXA’s mission to find a cure for Fragile X syndrome. Your donation can make a difference in the lives of those affected.
Read morePioneering Community-Based Drug Development for Fragile X Syndrome
![Pioneering Community-Based Drug Development for Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2023/07/Steward-Lab-FRAXA-2-720x300.jpg)
Discover how FRAXA leverages Community-Based Drug Development to create impactful therapies for Fragile X syndrome. Join us as we reshape the future of rare disease treatment.
Read moreAllos Pharma Advances Phase 3 Clinical Trial Design for Potential Fragile X Syndrome Treatment, Arbaclofen
![Allos Pharma Advances Phase 3 Clinical Trial Design for Potential Fragile X Syndrome Treatment, Arbaclofen](https://www.fraxa.org/wp-content/uploads/2020/11/397686_4212565235804_452910278_n-e1605762012898-720x300.jpg)
Discover Allos Pharma’s advancements in a pivotal Phase 3 trial for Fragile X syndrome treatment, Arbaclofen. Learn how their FDA-informed trial design might finally bring hope to the Fragile X community.
Read moreBreakthrough Discoveries in Fragile X Research: Insights from Special Banbury Meeting on Curative Therapies
![Breakthrough Discoveries in Fragile X Research: Insights from Special Banbury Meeting on Curative Therapies 2023 Fragile X Research Banbury Meeting (1)](https://www.fraxa.org/wp-content/uploads/2023/05/2023-Fragile-X-Research-Banbury-Meeting-1-720x300.jpg)
Explore the latest breakthroughs in Fragile X research unveiled at the recent Banbury Meeting. Discover novel strategies, from gene therapy to protein replacement, that bring hope for curative therapies.
Read moreComing Together for Rare Disease Day 2023
![Coming Together for Rare Disease Day 2023](https://www.fraxa.org/wp-content/uploads/2023/02/Rare-Disease-Day-fi-720x300.png)
Today, February 28, we mark Rare Disease Day, a day dedicated to raising awareness about rare diseases and highlighting the need for continued research and collaboration. At FRAXA Research Foundation, we are committed to advancing research on Fragile X syndrome, one of the most common rare diseases worldwide.
Read moreValidating Novel Inhibitors of ERK Signalling to Treat Fragile X Syndrome
![Validating Novel Inhibitors of ERK Signalling to Treat Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2023/08/Ning-Cheng-team-720x300.jpg)
One promising treatment approach for Fragile X syndrome is to inhibit on a neuronal pathway, ERK. ERK inhibitors are also being studied as treatments for other disorders including autism.
This team has conducted pilot studies showing that ERK inhibitors are very effective in reversing signs of disease in Fragile X mice. With this grant from FRAXA they will take the next steps toward possible clinical trials of an ERK inhibitor for individuals who have Fragile X syndrome.
A Note of Thanks and Hope on This Giving Tuesday
![A Note of Thanks and Hope on This Giving Tuesday](https://www.fraxa.org/wp-content/uploads/2022/11/Katie-Parent-Video-fi-720x300.png)
Why is Fragile X research so important? Every advance in Fragile X brings us all closer to discovering treatments for autism and other brain disorders. We are truly grateful to everyone who has helped FRAXA fund groundbreaking research. Thanks to you, we have hope.
Read moreRepurposing FDA-Approved Drugs to Treat Major Depressive Disorder in Fragile X Syndrome
![Repurposing FDA-Approved Drugs to Treat Major Depressive Disorder in Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2021/05/Improving-Depression-in-Individuals-with-FX-Thumbnail-fi-720x300.png)
Did you know that depression is more common in those with autism and/or Fragile X? Even more disturbing is the discovery that current treatments for depression do not work in Fragile X mice. With this grant, the team will work to develop a rapid screening tool to identify FDA-approved drugs which can treat depression in people with Fragile X syndrome.
Read moremRNA Therapy for Fragile X Syndrome
![mRNA Therapy for Fragile X Syndrome](https://www.fraxa.org/wp-content/uploads/2022/04/Grant-750-Whitehead-fi-720x300.png)
Dr. Kathryn Whitehead, Associate Professor at Carnegie Mellon University, helped develop the revolutionary science behind the COVID-19 vaccines. With a $103,000 grant from FRAXA, her team will now adapt this technology to deliver the missing Fragile X protein, to treat people who have Fragile X syndrome.
Read moreVLM Commodities Charity Week Raises $10,000 for Fragile X Research
![VLM Commodities Charity Week Raises $10,000 for Fragile X Research](https://www.fraxa.org/wp-content/uploads/2022/04/Lou-Little-Lou-720x300.png)
“We are often asked how we can do this, live with the challenges of Fragile X, day in and day out” Lou shared, “It’s just what we do. We keep going forward. FRAXA gives life and purpose to our community. I look forward to Charity Week being an annual VLM event and supporting the work FRAXA does.”
Read moreAggression, Other Fragile X Behaviors Tend to Ease Over Teenage Years
![Aggression, Other Fragile X Behaviors Tend to Ease Over Teenage Years](https://www.fraxa.org/wp-content/uploads/2022/04/Aggression-Other-Fragile-X-Behaviors-Tend-to-Ease-Over-Teenage-Years-700x300.png)
Behavioral problems such as hyperactivity and aggression are generally more frequent in younger children with Fragile X syndrome, becoming less common as they grow through adolescence and journey toward adulthood, researchers report.
Read moreGordon Research Conference for Fragile X and Autism-Related Disorders, Explained
![Gordon Research Conference for Fragile X and Autism-Related Disorders, Explained](https://www.fraxa.org/wp-content/uploads/2022/03/Explained-GRC-yt-720x300.png)
The Fragile X and Autism-Related Disorders Gordon Research Conference is a biannual event that provides an international forum for the presentation and discussion of frontier research in these conditions. Dr. Mike Tranfaglia explains why this is the premier conference for researchers and the scientific community.
Read more